Annexon Inc. (NASDAQ: ANNX)
$6.18
+0.1000 ( +1.65% ) 3.4M
Annexon Inc is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain, and eye. Its pipeline is based on its platform technology addressing well-researched classical complement-mediated autoimmune and neurodegenerative disease processes, both of which are triggered by aberrant activation of C1q. Its pipeline of product candidates is designed to block the activity of C1q and the entire classical complement pathway in a broad set of complement-mediated diseases. Its product candidates are ANX005, for autoimmune & neurodegenerative disorders; ANX007, for neurodegenerative ophthalmic disorders; ANX1502 for Oral small molecule; and ANX009, for systemic autoimmune diseases.
Market Data
Open
$6.18
Previous close
$6.08
Volume
3.4M
Market cap
$650.40M
Day range
$5.87 - $6.25
52 week range
$1.57 - $8.40
SEC Fillings
Form Type | Description | Pages | Date |
---|---|---|---|
4 | Insider transactions | 1 | Jun 05, 2024 |
8-k | 8K-related | 51 | Jun 04, 2024 |
10-q | Quarterly Reports | 54 | May 13, 2024 |
8-k | 8K-related | 13 | May 13, 2024 |
8-k | 8K-related | 15 | May 07, 2024 |
4 | Insider transactions | 1 | May 03, 2024 |
ars | Annual reports | 1 | Apr 25, 2024 |
def | Proxies and info statements | 6 | Apr 25, 2024 |
4 | Insider transactions | 1 | Apr 10, 2024 |
10-k | Annual reports | 73 | Mar 26, 2024 |